Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?

Osteoporosis (OP) is a relevant disease involving a high social and economic impact on public health worldwide [1]. OP is characterized by reduced bone mass, which raises the risk of fractures. Today, the first line of treatment for OP is antiresorptive (AR) drugs. AR significantly increases bone mass and reduces the risk of fractures by blocking the number and activity of bone-resorbing cells (osteoclasts). Moreover, AR minimizes bone loss in oncology diseases, such as primary bone tumors (i.e., osteosarcoma) and breast or prostate cancer bone metastasis [2]. …